FDA has issued revision 2 to the cGMP Guidance for Outsourcing Facilities.
The draft guidance is available here. And is open for public comment.
As noted in the FDA announcement: This revised draft guidance describes FDA’s policies regarding compounders registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as outsourcing facilities and the current good manufacturing practice (CGMP) requirements in FDA regulations. Based on feedback from stakeholders and comments received on the initial draft guidance, the guidance is being revised, in part, to reflect further consideration of how CGMP requirements should be applied in light of the size and scope of an outsourcing facility’s operations.
Next CGMP Consultants Recommended in FDA Warning Letters
Moa Feldenheimer
Marketing and Corporate Development Director - Moa has more than 30 years of experience in Marketing and Publishing, which includes the healthcare sector for the last few years. He brings a strong background of marketing strategy, content marketing and Mergers and Acquisitions.
Marketing and Corporate Development Director - Moa has more than 30 years of experience in Marketing and Publishing, which includes the healthcare sector for the last few years. He brings a strong background of marketing strategy, content marketing and Mergers and Acquisitions.
Skip to main content
